Securities code: 603122 securities abbreviation: Hefu China Announcement No.: 2022009 Hefu (China) Medical Technology Co., Ltd
Announcement of resolutions of the 8th meeting of the 1st board of supervisors
The board of supervisors and all supervisors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
1、 Meetings of the board of supervisors
The eighth meeting of the first board of supervisors of Hefu (China) Medical Technology Co., Ltd. (hereinafter referred to as "the company") was held on site in the company's conference room on the 20th floor of Guangqi building, 456 Hongcao Road, Shanghai on the afternoon of March 21, 2022. The notice of the meeting was sent by email or in writing on March 11, 2022. The meeting was presided over by Ms. Yan Shi, the chairman of the board of supervisors and 3 supervisors. The meeting was held in accordance with laws and regulations, the company law and the articles of association, and the resolutions of the meeting were legal and effective. The supervisors attending the meeting carefully considered all the proposals and formed the following resolutions through written voting:
2、 Deliberation at the meeting of the board of supervisors
1. The proposal on the work report of the board of supervisors in 2021 was reviewed and passed.
Voting results: 3 in favor, 0 against and 0 abstention.
This proposal still needs to be submitted to the general meeting of shareholders for deliberation.
2. The proposal on the company's 2021 annual report and its summary was reviewed and passed.
The board of supervisors believes that: (1) the preparation and review procedures of the company's 2021 annual report are standardized and legal, comply with laws, regulations, articles of association and various provisions of the company's internal management system, and the content is true, accurate and complete.
（2） The content and format of the company's 2021 annual report comply with the provisions of the China Securities Regulatory Commission and the Shanghai Stock Exchange, and the information contained truly and objectively reflects the company's financial situation and operating results in this quarter.
（3） No violation of confidentiality provisions was found among the personnel involved in the preparation and review of the 2021 annual report.
For details, please refer to the website of Shanghai Stock Exchange on the same day (www.sse. Com. CN.) Disclosed annual report of 2021 and summary of annual report of 2021.
Voting results: 3 in favor, 0 against and 0 abstention.
This proposal still needs to be submitted to the general meeting of shareholders for deliberation.
3. Deliberated and passed the proposal on the company's 2021 annual financial statement report.
Voting results: 3 in favor, 0 against and 0 abstention.
This proposal still needs to be submitted to the general meeting of shareholders for deliberation.
4. The proposal on the company's 2022 annual financial budget report was reviewed and passed
Voting results: 3 in favor, 0 against and 0 abstention.
This proposal still needs to be submitted to the general meeting of shareholders for deliberation.
5. The proposal on the prediction of the company's daily connected transactions in 2022 was reviewed and passed.
For details, please refer to the website of Shanghai Stock Exchange on the same day (www.sse. Com. CN.) Announcement on the prediction of the company's daily connected transactions in 2022 (Announcement No.: 2022013).
Voting results: 3 in favor, 0 against and 0 abstention.
6. The proposal on purchasing directors' liability insurance was deliberated and adopted.
The board of supervisors believes that purchasing liability insurance for the company and all directors, supervisors and senior managers can help improve the company's risk management system, reduce operational risks, protect the legitimate rights and interests of the company and all directors, supervisors and senior managers, promote the performance of relevant responsible personnel and ensure the healthy development of the company. The decision-making procedure of this matter is legal and compliant, and there is no situation that damages the interests of the company and all shareholders. The board of supervisors agreed to submit the proposal to the general meeting of shareholders of the company for deliberation.
All supervisors avoid voting on this proposal, which will be directly submitted to the general meeting of shareholders for deliberation.
7. The proposal on changing the implementation subject of some raised investment projects and using some raised funds to provide loans to wholly-owned subsidiaries to implement raised investment projects was reviewed and passed
For details, please refer to the website of Shanghai Stock Exchange on the same day (www.sse. Com. CN.) Announcement on changing the implementation subject of some raised investment projects and using some raised funds to provide loans to wholly-owned subsidiaries to implement raised investment projects (Announcement No.: 2022016).
Voting results: 3 in favor, 0 against and 0 abstention.
8. The proposal on the company's profit distribution plan for 2021 was reviewed and passed
For details, please refer to the website of Shanghai Stock Exchange on the same day (www.sse. Com. CN.) Announcement of profit distribution plan in 2021 (Announcement No.: 2022011).
Voting results: 3 in favor, 0 against and 0 abstention.
This proposal still needs to be submitted to the general meeting of shareholders for deliberation.
3、 Documents for future reference
1. Resolutions of the eighth meeting of the first board of supervisors.
It is hereby announced.
Board of supervisors of Hefu (China) Medical Technology Co., Ltd. March 22, 2022
